A file image of Memsift Innovations Improved Membrane Distillation (IMD) system – essential panel and the membrane rack.
Singapore-based Memsift Innovations has bagged a $1.62-million business contract from a number one Fortune 100 pharmaceutical firm to revolutionise industrial liquid waste therapy and nil liquid discharge options.
The global pharma large initiated a technical feasibility research in 2019. The research aimed to evaluate the feasibility of utilising TS-30 Improved Membrane Distillation system to deal with liquid waste resulted in decreasing liquid waste quantity by greater than 90% whereas recovering high-quality nitrogen fertiliser, the waste-to-value added product firm stated in an announcement.
Building on the optimistic outcomes of the feasibility research, a full-scale onsite pilot program was unveiled in early 2022 and has been in steady operation for over a yr.
“This bold move will not only enable the pharma major to achieve more than 90% cost savings in waste disposal but also reduce its carbon footprint by up to 80% compared to conventional disposal and incineration methods, resulting in an estimated reduction of 490 tons of CO2 emissions annually,” stated Memsift Innovations Pte. Ltd.’s Founder & CEO J. Antony Prince.
The business implementation of this undertaking is slated to start within the first quarter of 2024.
%20system%20-%20main%20panel%20and%20the%20membrane%20rack.jpg&description=Memsift+Innovations+bags+%241.62+mn+order+from+global+pharma+major){kind=link}